Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab and Radiotherapy With or Without Concurrent Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma
NCT07177443Phase 3Recruiting
- Start
- Sep 2025
- Primary completion
- Dec 2035
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab in nasopharyngeal carcinoma (NPC). Started Sep 2025; status: recruiting.
02
Drugs
serplulimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07177443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07177443.